Rifaximin therapy for patients with irritable bowel syndrome without constipation
about
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular riskIntestinal microbiota in functional bowel disorders: a Rome foundation reportUse of rifaximin in gastrointestinal and liver diseasesClinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndromeNew and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologistsDiagnosis and treatment of diarrhea-predominant irritable bowel syndromeGut microbiota role in irritable bowel syndrome: New therapeutic strategiesRifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled TrialsEffect of rifaximin on gut microbiota composition in advanced liver disease and its complicationsGut-Microbiota-Brain Axis and Its Effect on Neuropsychiatric Disorders With Suspected Immune DysregulationThe rise of multiple imputation: a review of the reporting and implementation of the method in medical researchProfile of rifaximin and its potential in the treatment of irritable bowel syndromeAbdominal bloating: pathophysiology and treatmentGut microbiota and gastrointestinal health: current concepts and future directionsIrritable bowel syndrome: a concise review of current treatment conceptsUpper gastrointestinal microbiota and digestive diseasesUnraveling the ties between irritable bowel syndrome and intestinal microbiotaMeasuring response in the gastrointestinal tract in systemic sclerosisBrain-gut axis: from basic understanding to treatment of IBS and related disordersEnteric bacterial proteases in inflammatory bowel disease- pathophysiology and clinical implicationsMethanogens, methane and gastrointestinal motilityBiomarkers of Irritable Bowel SyndromeModulation of microbiota as treatment for intestinal inflammatory disorders: An uptodateGut bacteria in health and diseaseRandomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind studyThe gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems.Stress and visceral pain: from animal models to clinical therapiesRifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats.It's a gut feeling: how the gut microbiota affects the state of mind.Review article: the treatment of functional abdominal bloating and distension.Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome.Prevalence, comorbidity, and risk factors for functional bowel symptoms: a population-based survey in Northern Norway.Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.IBS and the role of otilonium bromide.A combined nutrient and lactulose challenge test allows symptom-based clustering of patients with irritable bowel syndrome.Diagnosis and management of small intestinal bacterial overgrowth.Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial.Effect of a low-flatulogenic diet in patients with flatulence and functional digestive symptoms.Breath tests and irritable bowel syndrome.Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome
P2860
Q24603491-778F7800-9DBE-46C8-BA20-6EDD5B324736Q24631357-F959B6BD-33E3-404A-B1F1-713660D78F5AQ26740201-F5BD7CDB-92DA-4D02-AB28-2AB61DA70CEAQ26743440-E37117F5-317E-47E4-A291-8CF43595D607Q26748617-8A1D9491-D57E-455C-84F5-1CB3FAB53D23Q26765272-7BDC2855-80CB-4EBE-B7BB-E33FAB300977Q26768550-99EB8D08-369B-497E-8A2E-B4D69D9C8342Q26772962-F468B9B2-FCA1-44A4-813D-1737A7440019Q26775927-682F92E7-920E-46F7-A553-7CE77CB2E591Q26824638-41DB8018-F079-476E-83D0-E2391C7554DBQ26828889-4397896B-B2DA-4BC4-8C72-54F51C6C01C6Q26829363-BE0C4980-AA9F-4098-8A87-F5CE81EB6F50Q26851622-76855BED-A728-4E52-B6E5-2746D3D6E3E1Q26865880-99E90CD4-BAC8-4147-87E1-539DB1723DA2Q26996547-12B2DC2A-C7F2-462A-B41E-7625E8147518Q27002380-288C687F-D31E-495B-B186-E81682692415Q27004645-E16CF541-A852-4DEE-AE48-FE3AA1F72E7DQ27022416-0D47145F-57E6-4D64-86C3-04C8AAE2DBBDQ27024801-7CD2AA59-D2EC-46AC-8CB4-9CAF3C403144Q27027602-0A876813-B2B5-4733-887F-1EFEE30A418DQ27693339-2FF9CC78-D673-4D05-B27B-5B6279E9978EQ28069902-72D8727E-38A8-4F71-9388-5DC89615E3DDQ28072437-57016B93-5ACD-4944-92AD-5A8138C6200DQ28238138-018437AE-0C5D-4B96-9BB6-E3C22FECADEAQ28239840-0107C601-4E60-4660-B9C0-9334D1B51392Q30415125-8EA1A202-1070-4536-BD2F-CE4427C70D9EQ30459512-C93396BC-5EAE-4DD1-9E1F-C6AC6B04D311Q31142368-3E194594-DC69-4628-B72A-B7C8AC6A2C84Q31154556-780F38B1-9339-46F6-99D5-5C85CB0744A1Q33450132-B497FB23-FB3A-4C10-A746-676FB28B8BFBQ33451900-AB59E2B4-21CA-46DE-BE25-DA700F4A50B3Q33456089-05C010E3-B744-4F56-B1D5-E1B25CEAAD62Q33456102-C8BDF83F-5F9D-4874-AE65-CF10E4410B84Q33456428-B8D5E201-7DC5-4215-A30F-50203AEB01C2Q33457676-573E5628-A974-4CF2-B988-64CF1009371BQ33457767-B083A52C-3188-4B6E-AFB6-36ED65CFBC7FQ33459323-602C95D5-A1D5-4C51-919A-1CB80455717EQ33460827-85439211-3406-4F53-97A7-EF24AB8BBDCFQ33462070-7F8C7E99-9D3F-44E6-8A3D-97229CBF80C6Q33463153-250E6A46-7F4D-4B69-AA56-E92CFFF2C9C6
P2860
Rifaximin therapy for patients with irritable bowel syndrome without constipation
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Rifaximin therapy for patients with irritable bowel syndrome without constipation
@ast
Rifaximin therapy for patients with irritable bowel syndrome without constipation
@en
Rifaximin therapy for patients with irritable bowel syndrome without constipation
@nl
type
label
Rifaximin therapy for patients with irritable bowel syndrome without constipation
@ast
Rifaximin therapy for patients with irritable bowel syndrome without constipation
@en
Rifaximin therapy for patients with irritable bowel syndrome without constipation
@nl
prefLabel
Rifaximin therapy for patients with irritable bowel syndrome without constipation
@ast
Rifaximin therapy for patients with irritable bowel syndrome without constipation
@en
Rifaximin therapy for patients with irritable bowel syndrome without constipation
@nl
P2093
P3181
P356
P1476
Rifaximin therapy for patients with irritable bowel syndrome without constipation
@en
P2093
Anthony Lembo
Audrey L Shaw
Enoch Bortey
Salam Zakko
Shadreck M Mareya
William D Chey
William P Forbes
Yehuda Ringel
P3181
P356
10.1056/NEJMOA1004409
P407
P577
2011-01-06T00:00:00Z